- Kite, a Gilead Sciences Inc company GILD, announced a global strategic collaboration to co-develop and co-commercialize Arcellx Inc's ACLX lead late-stage product candidate, CART-ddBCMA, for relapsed or refractory multiple myeloma.
- Kite and Arcellx will jointly advance the CART-ddBCMA asset.
- Arcellx will receive an upfront payment of $225 million, a $100 million equity investment, and other potential contingent payments.
- The companies will share development, clinical trial, and commercialization costs for CART-ddBCMA and will jointly commercialize the product and split U.S. profits 50/50.
- Outside the U.S., Kite will commercialize the product.
- Arcellx also announced interim CART-ddBCMA Phase 1 results (October 31, 2022 cutoff date), demonstrating deep and durable responses.
- Of the 38 evaluable patients with a median follow-up of 15 months, a 100% overall response rate (ORR) was achieved in all patients.
- 27 of 38 (71%) evaluable patients achieved complete response (CR).
- CART-ddBCMA continues to be well-tolerated, showing no tissue-targeted toxicities and no cases of delayed neurotoxicity events or parkinsonian symptoms.
- The company also initiated a Phase 1 study evaluating the safety of ACLX-002 in adults with relapsed and/or refractory acute myeloid leukemia (AML) or high-risk myelodysplastic syndrome (MDS).
- The secondary objectives are to measure the anti-tumor activity and pharmacokinetics of both SparX-002 and ARC-T cells.
- Price Action: ACLX shares are up 22.5% at $26.57 on the last check Friday.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in
